X-154532257-C-T

Variant names:

Variant summary

Our verdict is Pathogenic. The variant received 12 ACMG points: 14P and 2B. PM1PM5PP2PP3PP5_Very_StrongBP4BS2_Supporting

The NM_001360016.2(G6PD):c.1388G>A(p.Arg463His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000117 in 1,209,616 control chromosomes in the GnomAD database, including 1 homozygotes. There are 42 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R463C) has been classified as Likely pathogenic.

Frequency

Genomes: 𝑓 0.00017 ( 0 hom., 8 hem., cov: 23)

Exomes 𝑓: 0.00011 ( 1 hom. 34 hem. )

Consequence

G6PD
NM_001360016.2 missense

Scores

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:18U:1O:5

Conservation

PhyloP100: 7.34

Publications

161 publications found

Variant links:

Genes affected

G6PD (HGNC:4057): (glucose-6-phosphate dehydrogenase) This gene encodes glucose-6-phosphate dehydrogenase. This protein is a cytosolic enzyme encoded by a housekeeping X-linked gene whose main function is to produce NADPH, a key electron donor in the defense against oxidizing agents and in reductive biosynthetic reactions. G6PD is remarkable for its genetic diversity. Many variants of G6PD, mostly produced from missense mutations, have been described with wide ranging levels of enzyme activity and associated clinical symptoms. G6PD deficiency may cause neonatal jaundice, acute hemolysis, or severe chronic non-spherocytic hemolytic anemia. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

G6PD Gene-Disease associations (from GenCC):

anemia, nonspherocytic hemolytic, due to G6PD deficiency
Inheritance: XL Classification: DEFINITIVE, STRONG Submitted by: ClinGen, Ambry Genetics, Labcorp Genetics (formerly Invitae)
G6PD deficiency
Inheritance: XL Classification: DEFINITIVE Submitted by: ClinGen
class I glucose-6-phosphate dehydrogenase deficiency
Inheritance: XL Classification: SUPPORTIVE Submitted by: Orphanet

G6PD links:

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 12 ACMG points.

PM1

In a hotspot region, there are 6 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 3 uncertain in NM_001360016.2

PM5

Other missense variant is known to change same aminoacid residue: Variant chrX-154532258-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 1722638.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

PP2

Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 185 curated pathogenic missense variants (we use a threshold of 10). The gene has 42 curated benign missense variants. Gene score misZ: 2.0008 (below the threshold of 3.09). Trascript score misZ: NaN (below the threshold of 3.09). GenCC associations: The gene is linked to anemia, nonspherocytic hemolytic, due to G6PD deficiency, class I glucose-6-phosphate dehydrogenase deficiency, G6PD deficiency.

PP3

Multiple lines of computational evidence support a deleterious effect 7: BayesDel_addAF, BayesDel_noAF, M_CAP, MutationAssessor, PROVEAN, REVEL, REVEL [when AlphaMissense, max_spliceai, FATHMM_MKL, MetaRNN, MutationTaster was below the threshold]

PP5

Variant X-154532257-C-T is Pathogenic according to our data. Variant chrX-154532257-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 100059.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

BP4

Computational evidence support a benign effect (MetaRNN=0.043610394). . Strength limited to SUPPORTING due to the PP5.

BS2

High Hemizygotes in GnomAd4 at 8 XL geneVariant has number of hemizygotes lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
G6PD	NM_001360016.2 link	c.1388G>A	p.Arg463His	missense_variant	Exon 12 of 13	ENST00000393562.10	NP_001346945.1
G6PD	NM_000402.4 link	c.1478G>A	p.Arg493His	missense_variant	Exon 12 of 13		NP_000393.4	P11413-3
G6PD	NM_001042351.3 link	c.1388G>A	p.Arg463His	missense_variant	Exon 12 of 13		NP_001035810.1	P11413-1A0A384NL00

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
G6PD	ENST00000393562.10 link	c.1388G>A	p.Arg463His	missense_variant	Exon 12 of 13	1	NM_001360016.2	ENSP00000377192.3		P11413-1

Frequencies

GnomAD3 genomes

AF:

0.000170

AC:

AN:

111763

Hom.:

Cov.:

show subpopulations

Gnomad AFR

AF:

0.00

Gnomad AMI

AF:

0.00

Gnomad AMR

AF:

0.00

Gnomad ASJ

AF:

0.00

Gnomad EAS

AF:

0.00534

Gnomad SAS

AF:

0.00

Gnomad FIN

AF:

0.00

Gnomad MID

AF:

0.00

Gnomad NFE

AF:

0.00

Gnomad OTH

AF:

0.00

GnomAD2 exomes

AF:

0.000554

AC:

101

AN:

182202

AF XY:

0.000477

show subpopulations

Gnomad AFR exome

AF:

0.00

Gnomad AMR exome

AF:

0.00

Gnomad ASJ exome

AF:

0.00

Gnomad EAS exome

AF:

0.00717

Gnomad FIN exome

AF:

0.00

Gnomad NFE exome

AF:

0.00

Gnomad OTH exome

AF:

0.000223

GnomAD4 exome

AF:

0.000112

AC:

123

AN:

1097804

Hom.:

Cov.:

AF XY:

0.0000936

AC XY:

AN XY:

363230

show subpopulations

African (AFR)

AF:

0.00

AC:

AN:

26397

American (AMR)

AF:

0.0000284

AC:

AN:

35190

Ashkenazi Jewish (ASJ)

AF:

0.00

AC:

AN:

19377

East Asian (EAS)

AF:

0.00358

AC:

108

AN:

30197

South Asian (SAS)

AF:

0.0000739

AC:

AN:

54098

European-Finnish (FIN)

AF:

0.00

AC:

AN:

40380

Middle Eastern (MID)

AF:

0.000243

AC:

AN:

4123

European-Non Finnish (NFE)

AF:

0.00000119

AC:

AN:

841964

Other (OTH)

AF:

0.000174

AC:

AN:

46078

Allele Balance Distribution

Red line indicates average allele balance

Average allele balance: 0.474

Heterozygous variant carriers

0.00

0.20

0.40

0.60

0.80

0.95

Allele balance

GnomAD4 genome

AF:

0.000170

AC:

AN:

111812

Hom.:

Cov.:

AF XY:

0.000235

AC XY:

AN XY:

34042

show subpopulations

African (AFR)

AF:

0.00

AC:

AN:

30847

American (AMR)

AF:

0.00

AC:

AN:

10611

Ashkenazi Jewish (ASJ)

AF:

0.00

AC:

AN:

2640

East Asian (EAS)

AF:

0.00535

AC:

AN:

3549

South Asian (SAS)

AF:

0.00

AC:

AN:

2699

European-Finnish (FIN)

AF:

0.00

AC:

AN:

6063

Middle Eastern (MID)

AF:

0.00

AC:

AN:

217

European-Non Finnish (NFE)

AF:

0.00

AC:

AN:

52978

Other (OTH)

AF:

0.00

AC:

AN:

1531

Allele Balance Distribution

Red line indicates average allele balance

Average allele balance: 0.489

Heterozygous variant carriers

0.00

0.20

0.40

0.60

0.80

0.95

Allele balance

Alfa

AF:

0.0000703

Hom.:

Bravo

AF:

0.000128

ExAC

AF:

0.000428

AC:

ClinVar

Significance: Conflicting classifications of pathogenicity

Submissions summary: Pathogenic:18Uncertain:1Other:5

Revision: criteria provided, conflicting classifications

LINK: link

Submissions by phenotype

Anemia, nonspherocytic hemolytic, due to G6PD deficiency

Pathogenic:8Uncertain:1

Jan 25, 2024

3billion

Significance:Uncertain significance

Review Status:criteria provided, single submitter

Collection Method:clinical testing

The variant is observed at an allele frequency greater than expected for the associated disorder in the gnomAD v2.1.1 dataset and therefore considered benign. The variant is observed as hemizygous in at least two unrelated individuals/adults in the gnomAD v.2.1.1 dataset. Predicted Consequence/Location: The variant is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reported. Missense changes are a common disease-causing mechanism. In silico tool predictions suggest damaging effect of the variant on gene or gene product [REVEL: 0.87 (>=0.6, sensitivity 0.68 and specificity 0.92); 3Cnet: 0.96 (>=0.6, sensitivity 0.72 and precision 0.9)]. Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000100059 /PMID: 1953767). Different missense changes at the same codon (p.Arg463Cys, p.Arg463Leu, p.Arg463Ser) have been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV001722637, VCV001722638, VCV002504081 /PMID: 12064920, 9192788). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. -

May 04, 2022

Mendelics

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Jan 19, 2024

Revvity Omics, Revvity

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Sep 23, 2024

Victorian Clinical Genetics Services, Murdoch Childrens Research Institute

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with G6PD deficient hemolytic anemia (favism) (MIM#300908). (I) 0109 - This gene is associated with X-linked recessive disease. Hemizygous males and homozygous females are commonly affected, however some heterozygous female carriers can also be affected depending on X inactivation. (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to histidine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (71 heterozygotes, 1 homozygote, 33 hemizygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (0 heterozygotes, 0 homozygotes, 1 hemizygote). (I) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated glucose-6-phosphate dehydrogenase, C-terminal domain (DECIPHER). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. Also known as the Kaiping variant, it is one the most common pathogenic alleles amongst the Chinese population; and is classified as a WHO class II variant (severe deficiency) (PMID: 33051526). In addition, it is consistently classified as pathogenic by diagnostic laboratories in ClinVar. (SP) 1207 - Parental origin of the variant is unresolved (duo analysis, father not tested). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -

Aug 04, 2022

Molecular Genetics, Royal Melbourne Hospital

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This sequence change in G6PD is predicted to replace arginine with histidine at codon 463, p.(Arg463His). The arginine residue is highly conserved (100 vertebrates, UCSC), and is located in the C-terminal glucose-6-phosphate dehydrogenase domain. There is a small physicochemical difference between arginine and histidine. The highest population minor allele frequency in gnomAD v2.1 is 0.7% (104/14,782 alleles, 1 homozygote, 32 hemizygotes) in the East Asian population. This variant is the most common cause of glucose-6-phosphate dehydrogenase (G6PD) deficiency in China (also known as Kaiping). It has been detected in hemizygous in affected males and compound heterozygous with a second pathogenic variant or homozygous in affected females. Individuals with this variant display reduced G6PD activity in their cells, with female heterozygous carriers demonstrating moderate deficiency (PMID: 33051526). Multiple lines of computational evidence predict a deleterious effect for the missense substitution (6/6 algorithms). Based on the classification scheme RMH Modified ACMG Guidelines v1.5.1, this variant is classified as PATHOGENIC. Following criteria are met: PM3_VeryStrong, PP3, PP4. -

Aug 12, 2022

Dunham Lab, University of Washington

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:curation

Variant found in unrelated hemizygotes with deficiency, some with anemia, jaundice, and favism, and one with CNSHA (PS4_M, PP4). Segregates with deficiency in a family (PP1). Decreased activity in red blood cells (1-44%) and when expressed in E. coli (PS3). Predicted to be disease causing by Mutation Taster and probably damaging by PolyPhen (PP3). Below expected carrier frequency in gnomAD (PM2). Reported as pathogenic by multiple clinical testing groups (PP5). Post_P 0.999 (odds of pathogenicity 6563, Prior_P 0.1). -

Department of Traditional Chinese Medicine, Fujian Provincial Hospital

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:research

We found the mutant NM_001360016.2:c.1388G>A in a young female patient who presented with jaundice and abnormal liver function by Next-generation sequencing. According to the ACMG guidelines, this mutation conforms to: PS3 (Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.); PP3_Moderate (Multiple lines of computational evidence support a deleterious effect on the gene or gene product.); PS4_Moderate (The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls.); PP1 (Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.); and PP4 (Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.) . Therefore, this mutation point is considered to be pathogenic. -

Feb 24, 2023

Department of Pathology and Laboratory Medicine, Sinai Health System

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:research

- -

Jan 23, 2025

Labcorp Genetics (formerly Invitae), Labcorp

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 463 of the G6PD protein (p.Arg463His). This variant is present in population databases (rs72554664, gnomAD 0.7%), and has an allele count higher than expected for a pathogenic variant. This variant has been described as a common cause of glucose-6-phosphate dehydrogenase deficiency in southeast Asia, although it has also been reported in affected individuals from other populations (PMID: 9589612, 30315739, 17726510, 21446359, 15906717, 15223006, 20236109). This variant is also known as Kaiping. ClinVar contains an entry for this variant (Variation ID: 100059). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt G6PD protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. -

not provided

Pathogenic:4

Dec 22, 2023

ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

The G6PD c.1388G>A; p.Arg463His variant (rs72554664), also known as G6PD Kaiping, is reported in the literature as a common G6PD deficiency variant in Asian populations (Chiu 1991, Fu 2018, Li 1998, Nuchprayoon 2002). This variant is reported in ClinVar (Variation ID: 100059) and is found in the East Asian population with an allele frequency of 0.70% (104/14,782 alleles, including 32 hemizygotes and a single homozygote) in the Genome Aggregation Database. Computational analyses predict that this variant is deleterious (REVEL: 0.869). Additionally, other variants at this codon (c.1387C>T; p.Arg463Cys, c.1387C>A; p.Arg463Ser) have been reported in individuals with G6PD deficiency (Hirono 1997, Rodrigues 2002). Based on available information, this variant is considered to be pathogenic. References: Chiu DT et al. Two commonly occurring nucleotide base substitutions in Chinese G6PD variants. Biochem Biophys Res Commun. 1991 Oct 31. PMID: 1953767. Fu C et al. Newborn screening of glucose-6-phosphate dehydrogenase deficiency in Guangxi, China: determination of optimal cutoff value to identify heterozygous female neonates. Sci Rep. 2018 Jan 16. PMID: 29339739. Hirono A et al. Molecular analysis of eight biochemically unique glucose-6-phosphate dehydrogenase variants found in Japan. Blood. 1997 Jun 15. PMID: 9192788. Li P et al. Analysis of common mutations and associated haplotypes in Chinese patients with glucose-6-phosphate dehydrogenase deficiency. Biochem Mol Biol Int. 1998 Dec. PMID: 9891846. Nuchprayoon I et al. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Thailand: G6PD Viangchan (871G>A) is the most common deficiency variant in the Thai population. Hum Mutat. 2002 Feb. PMID: 11793482. Rodrigues MO et al. Glucose-6-phosphate dehydrogenase deficiency in Portugal: biochemical and mutational profiles, heterogeneity, and haplotype association. Blood Cells Mol Dis. 2002 Mar-Apr. PMID: 12064920. -

May 01, 2023

CeGaT Center for Human Genetics Tuebingen

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

G6PD: PS3, PM1, PP1:Moderate, PP3, PS4:Supporting -

Mar 11, 2024

GeneDx

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

Observed in hemizygous state in several unrelated patients referred for genetic testing at GeneDx and in published literature and not observed in hemizygous state in controls (PMID: 18270558, 14505231, 9891846); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 15625830, 8935319, 23313052, 25440321, 20236109, 7390473, 29783823, 15766741, 7327562, 18270558, 11793482, 12497642, 15316963, 18046504, 34659341, 21931771, 29339739, 18329300, 24958328, 25775246, 26829728, 29702993, 29783822, 15223006, 17587269, 23006493, 15727905, 21874587, 16155737, 16331553, 16528451, 15476167, 17018380, 16513531, 16329560, 11295127, 16927025, 22938511, 14505231, 1953767, 9891846, 28376293, 31628766, 33069889, 32959227, 34953813, 36071769, 35611242, 29251006, 35193651, 35313968, 12215013, 34272389) -

May 16, 2013

Eurofins Ntd Llc (ga)

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Malaria, susceptibility to;C2720289:Anemia, nonspherocytic hemolytic, due to G6PD deficiency

Pathogenic:2

Juno Genomics, Hangzhou Juno Genomics, Inc

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

PS4+PP4+PS3+PM5_Supporting -

Oct 31, 2018

Fulgent Genetics, Fulgent Genetics

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

G6PD deficiency

Pathogenic:2

Jan 06, 2020

Reproductive Health Research and Development, BGI Genomics

Significance:Pathogenic

Review Status:no assertion criteria provided

Collection Method:curation

NM_001042351.1:c.1388G>A in the G6PD gene has an allele frequency of 0.007 in East Asian subpopulation in the gnomAD database. This variant has been described as a common cause of glucose-6-phosphate dehydrogenase deficiency in Southeast Asia, although it has also been reported in affected individuals from other populations (PMID: 9589612, 30315739, 17726510, 21446359, 15906717, 15223006, 20236109). Experimental studies have shown that this missense change causes a significant reduction in enzyme activity and affinity for glucose-6-phosphate (PMID: 16607506). Pathogenic computational verdict because pathogenic predictions from DANN, DEOGEN2, FATHMM-MKL, M-CAP, MVP, MutationAssessor, MutationTaster, REVEL and SIFTT. aken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP Criteria applied: PS3; PS4; PP4. -

Apr 25, 2023

Illumina Laboratory Services, Illumina

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

The G6PD c.1478G>A (p.Arg493His) variant, also known as c.1388G>A (p.Arg463His), or G6PD Kaiping, is a missense variant. In the literature, this variant is reported as one of the most common pathogenic variants associated with glucose-6-phosphate dehydrogenase deficiency in the East Asian population (PMID: 36949502; 33051526). The highest frequency of this allele in the Genome Aggregation Database is 0.007036 in the East Asian population (version 2.1.1). This frequency is high but is consistent with disease prevalence estimates. Multiple lines of computational evidence suggest the variant may impact the gene or gene product. This variant has been classified as pathogenic by at least twelve submitters in ClinVar. Based on the available evidence, the c.1478G>A (p.Arg493His) variant is classified as pathogenic for glucose-6-phosphate dehydrogenase deficiency. -

Inborn genetic diseases

Pathogenic:1

Jun 10, 2016

Ambry Genetics

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Malaria, susceptibility to

Pathogenic:1

Mar 26, 2024

Baylor Genetics

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

G6PD DHON

Other:1

May 24, 2017

OMIM

Significance:other

Review Status:no assertion criteria provided

Collection Method:literature only

- -

G6PD SAPPORO-LIKE

Other:1

May 24, 2017

OMIM

Significance:other

Review Status:no assertion criteria provided

Collection Method:literature only

- -

G6PD ANANT

Other:1

May 24, 2017

OMIM

Significance:other

Review Status:no assertion criteria provided

Collection Method:literature only

- -

G6PD KAIPING

Other:1

May 24, 2017

OMIM

Significance:other

Review Status:no assertion criteria provided

Collection Method:literature only

- -

G6PD PETRICH-LIKE

Other:1

May 24, 2017

OMIM

Significance:other

Review Status:no assertion criteria provided

Collection Method:literature only

- -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

AlphaMissense

Benign

0.25

BayesDel_addAF

Pathogenic

0.38

BayesDel_noAF

Pathogenic

0.77

CADD

Uncertain

(source)

DANN

Uncertain

1.0

DEOGEN2

Pathogenic

0.97

D;D;D;.

FATHMM_MKL

Uncertain

0.84

LIST_S2

Pathogenic

0.99

.;.;D;D

M_CAP

Pathogenic

0.95

MetaRNN

Benign

0.044

T;T;T;T

MetaSVM

Pathogenic

0.97

MutationAssessor

Pathogenic

3.3

M;M;M;.

PhyloP100

7.3

PrimateAI

Uncertain

0.72

PROVEAN

Pathogenic

-4.5

.;.;D;D

REVEL

Pathogenic

0.87

Sift

Uncertain

0.0020

.;.;D;D

Sift4G

Uncertain

0.035

D;.;D;D

Polyphen

0.99

D;D;D;.

Vest4

0.77

MutPred

0.85

Loss of phosphorylation at T466 (P = 0.1664);Loss of phosphorylation at T466 (P = 0.1664);Loss of phosphorylation at T466 (P = 0.1664);.;

MVP

1.0

MPC

2.3

ClinPred

0.26

GERP RS

5.7

Varity_R

0.92

gMVP

0.90

Mutation Taster

=17/83

disease causing (ClinVar)

(source)

Splicing

Name

Calibrated prediction

Score

Prediction

SpliceAI score (max)

0.030

Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.

X-154532257-C-T

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

Publications

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

Age Distribution

Age Distribution

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

Other links and lift over